New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2014
10:00 EDTCVBF, SAIA, GOGO, CPST, PAAS, CCMP, MTB, G, RHT, SNI, JBHT, CX, AHT, ACTOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Actavis (ACT) upgraded to Buy from Neutral at Goldman... Ashford Hospitality (AHT) upgraded to Outperform from Neutral at RW Baird... CEMEX (CX) upgraded to Buy from Neutral at Sterne Agee... Capstone Turbine (CPST) upgraded to Outperform from Market Perform at FBR Capital... Genpact (G) upgraded to Buy from Neutral at Citigroup... Gogo (GOGO) upgraded to Overweight from Equal Weight at Evercore... J.B. Hunt (JBHT) upgraded to Buy from Hold at Wunderlich... M&T Bank (MTB) upgraded to Buy from Neutral at SunTrust... Saia, Inc. (SAIA) upgraded to Buy from Hold at Wunderlich... Scripps Networks (SNI) upgraded at Argus... Cabot Microelectronics (CCMP) upgraded at DA Davidson... CVB Financial (CVBF) upgraded to Outperform from Market Perform at Fig Partners... Red Hat (RHT) upgraded to Outperform from Market Perform at Cowen... Pan American Silver (PAAS) upgraded to Market Perform from Underperform at BMO Capital.
News For ACT;AHT;CPST;CX;G;GOGO;JBHT;MTB;SAIA;SNI;CCMP;CVBF;RHT;PAAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
February 18, 2015
09:48 EDTACTActavis Q4 'exceptional,' taking Allergan name 'wise,' says BMO Capital
BMO Capital says Actavis (ACT) is "firing on all cylinders" after reporting "exceptional" Q4 earnings on the strength of the company's North American Generics and International segment. BMO views the decision to adopt the Allergan (AGN) name as "wise" given the Botox maker's strong reputation. The firm keeps an Outperform rating on Actavis.
07:50 EDTACTActavis CEO says company gave appropriate guidance to analysts
Actavis (ACT) CEO Saunders said he believes that the company did provide appropriate guidance to analysts ahead of its earnings beat. Saunders sees the Allergan (AGN) deal closing by the end of this quarter or early next quarter. Saunders says tying R&D to a percentage of revenue "makes no sense to me," noting that Actavis will spend about $1.7B on R&D next year. Saunders says will do acquisition if opportunity arises, but not planning for M&A right now. Actavis CEO Brent Saunders is speaking on CNBC.
07:01 EDTACTActavis announces intention to adopt 'Allergan' corporate name
Subscribe for More Information
06:48 EDTACTActavis reports 9 mid-to-late-stage compounds in development
Subscribe for More Information
06:34 EDTACTActavis sees Allergan transaction completed in late Q1 or early Q2
06:33 EDTACTActavis sees FY15 standalone EPS $16.30-$17.30, consensus $16.63
Subscribe for More Information
06:31 EDTACTActavis reports Q4 EPS $3.91, consensus $3.67
Subscribe for More Information
February 17, 2015
18:17 EDTACTJANA Partners gives quarterly update on stakes
NEW STAKES: NCR (NCR), Liberty Ventures (LVNTA), Solarcity (SCTY), Computer Sciences Corp (CSC), Salix (SLXP), and Applied Materials (AMAT). INCREASED STAKES: Hertz (HTZ), Valeant (VRX), Walgreens Boots Alliance (WBA), Rackspace (RAX), and HD Supply (HDS). DECREASED STAKES: AIG (AIG), Actavis (ACT), Charter (CHTR), AerCap (AER), and Energy Transfer Equity (ETE). LIQUIDATED STAKES: Equinix (EQIX), Cameron International (CAM), Dollar General (DG), QEP Resources (QEP), and Amgen (AMGN).
18:06 EDTACTPaulson & Co gives quarterly update on stakes
Subscribe for More Information
17:16 EDTACTActavis confirms temporary injunction related to generic Pulmicort RESPULES
Subscribe for More Information
17:02 EDTACTSoros Fund Management gives quarterly update on stakes
Subscribe for More Information
15:32 EDTACTNotable companies reporting before tomorrow's open
Subscribe for More Information
13:52 EDTACTEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:18 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
February 13, 2015
17:52 EDTACTThird Point gives quarterly update on stakes
Subscribe for More Information
16:32 EDTACTActavis launches generic Pulmicort RESPULES
Subscribe for More Information
10:00 EDTSNIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:54 EDTSNIScripps Networks estimates lowered on softer domestic ad view at Pacific Crest
Pacific Crest lowered its estimates for Scripps Networks citing a softer domestic advertising outlook, but said it sees a slightly positive risk/reward for shares based on the relative stability of its target affluent female demographic. The firm, which estimates a fair value on shares of $78, said a lower price could prompt a more positive view of the stock, on which it kept a Sector Perform rating.
08:32 EDTACTActavis to divest Pharmatech to TPG
Subscribe for More Information
05:53 EDTSNIScripps Networks downgraded to Neutral from Buy at MKM Partners
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use